Intramuscular fat, contained within muscle tissue, increases the risk of serious heart disease, regardless of other risk factors, a new study suggests.

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

Tom Nolan reviews this week’s research Exercise for 30 minutes three times a week on an exercise bike for a month; then make the sessions an hour long and add resistance training with two sets of ...

However, the benefits of beta-blockers in “stiff heart” heart failure are less clear. This condition, also known as heart ...

People with pockets of fat hidden within their muscles have a higher risk of dying from heart-related health problems, ...

GAITHERSBURG, MD, USA I2, 2025 I Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

AI model transforms heart failure care by precisely identifying cases and enhancing quality evaluations in clinical practice.

The following is a summary of “Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone ...

Both incident and recurrent heart failure hospitalization risk is associated with post-traumatic stress disorder among patients with CAD.

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.